Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Gynecologic 2Tumor-Agnostic 1Thoracic 1Other hematologic neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Rectal Neoplasms 1Papillomavirus Infections 1Oropharyngeal Neoplasms 1Carcinoma in Situ 1Anus Neoplasms 1

Interventions

Paclitaxel 77pembrolizumab 65Carboplatin 57Bevacizumab 57Specimen Handling 49Magnetic Resonance Spectroscopy 40Cisplatin 35olaparib 31Gemcitabine 27liposomal doxorubicin 25Biopsy 22Taxes 19Cyclophosphamide 18Topotecan 17Nivolumab 17Doxorubicin 16Immunoglobulin G 15niraparib 14Letrozole 14Disulfides 14lenvatinib 13fludarabine 13Surveys and Questionnaires 12Drug Therapy 12Radiotherapy 11Platinum 11atezolizumab 10abemaciclib 10durvalumab 9Fulvestrant 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Diphenhydramine × Gynecologic × 90 days × Clear all
NCT04432597 2026-05-18

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
39 enrolled
GastrointestinalGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Rectal Neoplasms

NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡